AlphAIAlphAI — Financial news for AI agents
investing.comOCT 201 min read$TVRD

Chardan initiates Tvardi Therapeutics stock with buy on STAT3 platform

Chardan initiated coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a buy rating and $8.00 price target, contingent on raising $35-40M for ulcerative colitis trials. The stock trades at $0.97, down 84% YoY, with a $15M market cap. Chardan estimates $1.6B peak sales at 20% success probability. H.C. Wainwright and Lucid Capital also rated TVRD Buy with $9.00 and $14.00 targets, respectively, citing positive clinical data.

Original reporting
investing.com
Published Oct 20, 2026, 11:34 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 11:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$TVRD
Neutral
medium confidence
Mentioned
$TVRD
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TVRDNeutralLow
01

Why it matters

Analyst initiation highlights financing as a key catalyst; no new trial data or regulatory decision is disclosed.

02

Market read

Coverage may attract short‑term interest but lacks a concrete catalyst; relevance is modest.

03

What to watch

Potential partnership or licensing deals not mentioned could change the risk profile.

Relevance 4/10Novelty 2/10Timing: no immediate catalyst

Background

Tvardi Therapeutics is a clinical‑stage biotech developing oral STAT3 inhibitors, currently facing a cash shortfall for its ulcerative colitis trial.

Company-level read

Ticker impact

$TVRDNeutralMedium confidence
Context

Chardan and other analysts initiated coverage on Tvardi Therapeutics with buy ratings and price targets, highlighting financing needs and trial updates.

Expected impact

potential modest upside if $35‑40M financing is confirmed, otherwise pressure from cash‑burn concerns

Evidence & confidence

Buy ratings are contingent on a capital raise; without it the stock may stay depressed near its 52‑week low.

Market effects

Sector

Limited; reflects broader analyst interest in STAT3 inhibitor biotech space.

Regional

Minimal; company is US‑based with niche market exposure.

Global

Low; no macro or sector‑wide impact.

Counterpoint

What could challenge this read

The stock may remain undervalued if financing is secured without diluting existing shareholders.

Key entities

  • company
    Tvardi Therapeutics Inc

    Clinical‑stage biotech developing STAT3 inhibitors.

  • analyst
    Chardan

    Initiated coverage with a buy rating.

Read at source← All news

Related articles

AUG 14
$TVRDMed

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

Tvardi Therapeutics, Inc. (TVRD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immu

SEC EDGAR 8-K4 min
JUL 7
$TVRDMedAI 8/10

Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109

Tvardi Therapeutics (NASDAQ: TVRD) reported Phase 1 results for its oral STAT3 inhibitor TTI-109. The company said TTI-109 rapidly converts to TTI-101, shows dose-proportional pharmacokinetics with exposures above the STAT3 IC50, and reduced STAT3-driven immune cell populations by up to 60% in exploratory analyses. It also cited shorter diarrhea duration vs TTI-101. TVRD shares rose sharply on the news.

investorideas.com4 min
JUL 7
$TVRDMed

Tvardi's TTI-109 Shows Improved Tolerability And Target Engagement In Phase 1 Study

Tvardi Therapeutics (TVRD) reported Phase 1 results for TTI-109, a phosphate prodrug of TTI-101. The drug converted rapidly and showed plasma exposure similar to TTI-101 at equivalent doses, with repeat dosing maintaining levels above the STAT3 inhibitory threshold for 21 days. Exploratory data showed up to 60% reductions in STAT3-driven immune cells and shorter diarrhea duration vs TTI-101. Phase 2 is planned pending funding.

rttnews.com3 min
JUL 7
$TVRDMedAI 8/10

Why Is Tvardi Therapeutics Stock Gaining Tuesday? - Tvardi Therapeutics (NASDAQ:TVRD)

Tvardi Therapeutics (NASDAQ:TVRD) reported Phase 1 results for TTI-109, a STAT3 inhibitor prodrug. The company said TTI-109 converted to TTI-101 within two hours, showed dose-proportional pharmacokinetics and target engagement, and had diarrhea events comparable to placebo (0.46 vs 3.35 days vs near-equivalent TTI-101). Shares rose ~49.75% to $3.01; plans to advance into dermatologic and gastrointestinal indications pending IND clearance and funding.

benzinga.com4 min
JUL 7
$TVRDMedAI 8/10

Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

Tvardi Therapeutics (NASDAQ: TVRD) reported Phase 1 results for TTI-109, a STAT3 inhibitor prodrug of TTI-101. The company said TTI-109 rapidly converts to TTI-101, shows dose-proportional PK with exposures above the STAT3 IC50, and reduced STAT3-driven immune cell populations by up to 60%. It plans to advance TTI-109 into dermatologic and GI diseases pending IND clearance and funding; webcast July 7, 8:30am ET.

manilatimes.net4 min